Oklahoma Israel Exchange
6608 N. Western Ave. #464
Oklahoma City, OK 73116
91450 Jerusalem, Israel
U.S.Fax No. 425-732-1379
The number of people in the United States suffering from a heart condition known as atrial fibrillation is
rising at an alarming rate.
Atrial fibrillation is a condition where the atria of the heart beat irregularly at very high rates, afflicting
more than 5 million Americans in 2010. Projections show that there will be 12 million fibrillation
patients by 2030.
The condition is the primary cause of strokes, worldwide, which disable or kill patients," said Dr.
Kenneth Dormer, Professor and Chair of the Physiology, Integrative Physiology and Pharmacology
Department at Liberty University in Virginia.
"The atrium quivers, the blood clots and the clots wind up in the brain," Dormer said of the potential
effects of atrial fibrillation. "The current technology for getting rid of that condition is often ineffective."
An inventor as well as a Ph.D Physiologist, Dormer had an idea for a magnetically targeted drug
delivery alternative to current methods for defeating atrial fibrillation. At a special meeting in 2007
arranged by the Oklahoma Israel Exchange, Dormer met Alex Harel, a retired Lt. Colonel in the
Israeli in the Israel Air Force who had been involved in several startup companies in Israel. One of
those companies had developed clinical electromagnets that are widely used in MRI machines
“At that meeting I met a team headed by professor Dormer that was working on magnetic particles,”
Harel said. “We started talking and one thing led to another. We decided there was common ground
for cooperation between us.”
Harel and Dormer founded Nanomed Targeting Systems in Oklahoma, in 2010, three years after the
Oklahoma Israel Exchange meeting.
The company obtained early grant funding from the Oklahoma Center for the Advancement of Science
and Technology. It has since received investment from the Virginia Center for Innovative Technology,
the Center for Integrative Nanotechnology, and from a leading investment group in Taiwan where a
B-round is in the works.
There is a growing need for the technology as the population ages. With a better, safer, less costly
solution, Nanomed Targeting Systems may have the answer.
Everything is looking good so far and we are cautiously optimistic,” Dr. Dormer said. “It would be great
to bring this project to fruition in Oklahoma, where it all began.”
Nanomed Targeting Systems uses magnetic nanoparticles to stop atrial fibrillation